Clearmind Medicine Publishes International Patent for Novel Weight Loss, Fatty Liver Therapy
Summary
Clearmind Medicine Inc. announced the publication of an international patent application for a novel combination therapy, integrating its proprietary MEAI with Palmitoylethanolamide (PEA) from NeuroThera Labs Inc., a subsidiary of SciSparc Ltd. (SPRC). This therapy targets weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD). The patent publication is a significant positive step for the clinical-stage biotech, protecting intellectual property in a rapidly growing market for obesity and liver health, potentially offering an alternative to GLP-1 agonists. This development is distinct from the company's recent DSMB approval for its AUD trial, adding a new and promising asset to its pipeline. Traders will watch for further clinical development and eventual patent grant for this therapy.
At the time of this announcement, CMND was trading at $1.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.99 to $52.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.